Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Semra Paydas

Showing results (121-130 of 135) with videos related to

Pageof 14
Sort By:
Neoplasma|January 9, 2023
Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective studyElvina Almuradova, Tugba Basoglu, Erdinc Nayir, et al.
Annals of Hematology|June 9, 2020
Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experienceHuseyin Bekoz, Murat Ozbalak, Nuri Karadurmus, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|June 12, 2020
Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group StudyBirol Yildiz, Ahmet Kucukarda, Ali Gokyer, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 4, 2026
Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)Cihan Erol, Esra Zeynelgil, Mutlu Hizal, et al.
Clinical Genitourinary Cancer|April 16, 2024
Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)Hatime Arzu Yasar, Burak Yasin Aktas, Gokhan Ucar, et al.
Leukemia & Lymphoma|September 13, 2024
A new scoring system to predict survival in elderly advanced stage Hodgkin lymphoma patientsÖzgür Mehtap, Tayfur Toptas, Mehmet S Dal, et al.
Journal of Cancer Research and Clinical Oncology|January 12, 2021
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) studyBurak Bilgin, Mehmet Ali Nahit Sendur, Sebnem Yucel, et al.
The Oncologist|October 13, 2019
The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRAUmut Disel, Russell Madison, Kumar Abhishek, et al.
Journal of Cancer Research and Clinical Oncology|April 17, 2023
Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) studyAhmet Bilici, Sinan Koca, Mustafa Karaagac, et al.
Medicine|May 24, 2024
A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacySaadettin Kilickap, Akin Ozturk, Nuri Karadurmus, et al.
Pageof 14

Showing results (121-130 of 135) with videos related to

Sort By:
Pageof 14
Neoplasma|January 9, 2023
Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective studyElvina Almuradova, Tugba Basoglu, Erdinc Nayir, et al.
Annals of Hematology|June 9, 2020
Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experienceHuseyin Bekoz, Murat Ozbalak, Nuri Karadurmus, et al.
Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|June 12, 2020
Does primary tumor localization has prognostic importance in seminoma patients?: Turkish Oncology Group StudyBirol Yildiz, Ahmet Kucukarda, Ali Gokyer, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 4, 2026
Efficacy and safety of second-line treatments in ALK mutation-positive advanced non-small cell lung cancer after second- or third-generation ALK inhibitors: Turkish Oncology Group real-life study (TOG study)Cihan Erol, Esra Zeynelgil, Mutlu Hizal, et al.
Clinical Genitourinary Cancer|April 16, 2024
Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)Hatime Arzu Yasar, Burak Yasin Aktas, Gokhan Ucar, et al.
Leukemia & Lymphoma|September 13, 2024
A new scoring system to predict survival in elderly advanced stage Hodgkin lymphoma patientsÖzgür Mehtap, Tayfur Toptas, Mehmet S Dal, et al.
Journal of Cancer Research and Clinical Oncology|January 12, 2021
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) studyBurak Bilgin, Mehmet Ali Nahit Sendur, Sebnem Yucel, et al.
The Oncologist|October 13, 2019
The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRAUmut Disel, Russell Madison, Kumar Abhishek, et al.
Journal of Cancer Research and Clinical Oncology|April 17, 2023
Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) studyAhmet Bilici, Sinan Koca, Mustafa Karaagac, et al.
Medicine|May 24, 2024
A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacySaadettin Kilickap, Akin Ozturk, Nuri Karadurmus, et al.
Pageof 14